Open AccessThe effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study
Author(s) -
Hirotsu Nobuo,
Saisho Yutaka,
Hasegawa Takahiro
Publication year - 2019
Publication title -
influenza and other respiratory viruses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.743
H-Index - 57
eISSN - 1750-2659
pISSN - 1750-2640
DOI - 10.1111/irv.12590
Subject(s) - zanamivir , neuraminidase , medicine , neuraminidase inhibitor , oseltamivir , observational study , influenza a virus , transmission (telecommunications) , prospective cohort study , virology , virus , covid-19 , disease , infectious disease (medical specialty) , electrical engineering , engineering
Background The relative ability of neuraminidase inhibitors ( NAI s) to reduce household influenza transmission when given to index patients is not established. Objectives To compare daily secondary infection rates ( SIR ) of influenza A (A/H1pdm and A/H3) and B in households of index patients treated with oseltamivir, zanamivir, laninamivir, or peramivir. Patients/Methods This Japanese, single‐center, prospective, observational study ( UMIN ‐ CTR : UMIN 000024650) enrolled index patients with confirmed influenza who were treated with an NAI during 6 influenza seasons (2010‐2016). Secondary infection patients were household members diagnosed with the same influenza subtype 1‐7 days after onset in the index patient. Daily SIR was calculated using a modified Reed‐Frost model. The rate of household members with secondary infection and proportion of households with any secondary infection were also calculated. Results Index patients with influenza A (n = 1146) or B (n = 661) were enrolled (~3400 total index and secondary patients). Daily SIR for all virus subtypes was highest when oseltamivir was used (eg, unadjusted estimate: type A, 1.47% vs 0.71%‐1.13%; type B, 1.30% vs 0.59%‐0.88%). Pairwise comparisons revealed significant differences in daily SIR between NAI s for influenza type A, type B, and subtype A/H3; for example, for type A, SIR was significantly higher with oseltamivir than with peramivir or zanamivir. The rate of household members with secondary infection and proportion of households with any secondary infection also varied between NAI s. Conclusions Neuraminidase inhibitors differed in their ability to reduce household influenza transmission; transmission was highest with oseltamivir. Physicians may consider effects on household transmission when deciding which NAI to prescribe.